Category - M&As and partnerships

Velsera Is Building an Ecosystem that Accelerates the R&D Loop and Democratizes Omics Data to Propel the Next Era of Precision Medicine

My most recent interview is with Gavin Nichols, the CEO of the newly formed company Velsera. Velsera launched in January 2023, after quietly acquiring the three companies Seven Bridges, UgenTec, and Pierian in mid...read more

Goodbye 2022 – Hello 2023

We say goodbye to 2022 which was full of significant developments in the life sciences, precision medicine, genetics, and genomics sectors. Notable new players in the next-generation sequencing field showcased their...read more

Time Is What We Want Most – Why Wasting Any More of It?

As many of us continuously experience, combing through the latest news in any scientific research area or a given commercial sector – whether it is to stay up-to-date in a specific field, view the latest trends in...read more

2021 – Precision Medicine linked with Genomic Medicine: A Work in Progress

Rebus Bio Continues Expansion of Industry-leading Spatial Omics Platform with Breakthrough High-Plex Technology

EEL assay overcomes well-known limitations in spatial biology SANTA CLARA, Calif. & STOCKHOLM–(BUSINESS WIRE)–Rebus Biosystems Inc, (“Rebus Bio”, “Rebus”), an Illumina Ventures-backed life science...read more